Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma

Cancer Drug Resistance, Год журнала: 2023, Номер 6(4), С. 858 - 73

Опубликована: Дек. 28, 2023

Renal cell carcinoma (RCC), the most prevalent type of kidney cancer, is a significant cause cancer morbidity and mortality worldwide. Antiangiogenic tyrosine kinase inhibitors (TKIs), in combination with immune checkpoint (ICIs), are among first-line treatment options for patients advanced RCC. These therapies target vascular endothelial growth factor receptor (VEGFR) pathway other kinases crucial to proliferation, survival, metastasis. TKIs have yielded substantial improvements progression-free survival (PFS) overall (OS) However, nearly all eventually progress on these drugs as resistance develops. This review provides an overview TKI RCC explores different mechanisms resistance, including upregulation alternative proangiogenic pathways, epithelial-mesenchymal transition (EMT), decreased intracellular drug concentrations due efflux pumps lysosomal sequestration, alterations tumor microenvironment bone marrow-derived cells (BMDCs) tumor-associated fibroblasts (TAFs), genetic factors such single nucleotide polymorphisms (SNPs). A comprehensive understanding opens door development innovative therapeutic approaches that can effectively overcome thereby improving outcomes

Язык: Английский

---

Role of Exosomes in Cancer and Aptamer-Modified Exosomes as a Promising Platform for Cancer Targeted Therapy

Biological Procedures Online, Год журнала: 2024, Номер 26(1)

Опубликована: Май 27, 2024

Abstract Exosomes are increasingly recognized as important mediators of intercellular communication in cancer biology. can be derived from cells well cellular components tumor microenvironment. After secretion, the exosomes carrying a wide range bioactive cargos ingested by local or distant recipient cells. The released act through variety mechanisms to elicit multiple biological effects and impact most if not all hallmarks cancer. Moreover, owing their excellent biocompatibility capability being easily engineered modified, currently exploited promising platform for targeted therapy. In this review, we first summarize current knowledge roles risk etiology, initiation progression cancer, underlying molecular mechanisms. aptamer-modified exosome therapy is then briefly introduced. We also discuss future directions emerging biology perspective

Язык: Английский

---

Cooperation between SIX1 and DHX9 transcriptionally regulates integrin-focal adhesion signaling mediated metastasis and sunitinib resistance in KIRC

Oncogene, Год журнала: 2024, Номер 43(39), С. 2951 - 2969

Опубликована: Авг. 22, 2024

Язык: Английский

---

Flexible Plasmonic Paper Substrates as Surface-Enhanced Raman Scattering (SERS) Biosensors Enable Sensitive Detection of Sunitinib Malate Drug

Plasmonics, Год журнала: 2023, Номер 19(1), С. 21 - 31

Опубликована: Июль 31, 2023

Язык: Английский

---

Enhanced Theranostic Efficacy of ⁸⁹Zr and ¹⁷⁷Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice

Molecular Pharmaceutics, Год журнала: 2024, Номер 21(5), С. 2544 - 2554

Опубликована: Апрель 8, 2024

Vascular endothelial growth factor (VEGF) targeted therapy serves as an important therapeutic approach for renal cancer, but its clinical effectiveness is unsatisfactory. Moreover, there a lack of reliable biomarkers preoperative assessment tumor VEGF expression. This study aimed to explore the potential further applications

Язык: Английский

---

PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway

British Journal of Cancer, Год журнала: 2024, Номер 131(2), С. 347 - 360

Опубликована: Май 31, 2024

Язык: Английский

---

Global trends of single cell sequence associated in cancer from 2011 to 2024: A bibliometric analysis

Heliyon, Год журнала: 2024, Номер 10(12), С. e32847 - e32847

Опубликована: Июнь 1, 2024

Exploring the different molecular and clinicopathological features of nodal cancer based on single cell sequencing can reveal intertumoral heterogeneity in cancer, provide new ideas for early diagnosis, treatment prognosis analysis cancer.

Язык: Английский

---

Efficacy and safety of atezolizumab plus bevacizumab versus sunitinib for metastatic renal cell carcinoma: a systematic review and meta-analysis

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Background Inhibitors targeting the programmed death ligand 1 (PD-L1) and angiogenesis inhibitors used for targeted treatments against metastatic renal cell carcinoma (mRCC) have garnered considerable attention in current years. Objective We aim to report latest most extensive meta-analysis providing an evidence-based comparison of safety efficacy outcomes atezolizumab plus bevacizumab versus sunitinib mRCC. Methods The databases PubMed, Web Science, Embase were searched up March 2023, studies comparing clinical patients with mRCC who given collected. methodological quality interest was assessed using risk bias assessment tool from Cochrane Collaboration. Results This involved six eligible published between 2018 2022. Combined analysis indicated that compared results enhanced progression-free survival (PFS), overall (OS), response rate (ORR), complete (CR), partial (PR), as well a lower incidence adverse events (AEs). time deterioration (TTD) based on MD Anderson Symptom Inventory (MDASI) showed improvement. However, TTD Brief Fatigue (BFI) fatigue severity, outcome stable disease, progressive disease no significant differences. Conclusion study demonstrated combined therapy is more effective safer than

Язык: Английский

---

Design and synthesis of antiproliferative 2-oxoindolin-3-ylidenes incorporating urea function with potential VEGFR-2 inhibitory properties

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Янв. 3, 2025

Язык: Английский

---

Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)

Frontiers in Pharmacology, Год журнала: 2025, Номер 15

Опубликована: Янв. 9, 2025

The emergence of targeted anti-tumor drugs has significantly prolonged the lifespan and improved prognosis cancer patients. Among these drugs, vascular endothelial growth factor (VEGF) inhibitors, particularly novel small molecule tyrosine kinase inhibitors (TKIs), are extensively employed as VEGF inhibitors; however, they also associated with a higher incidence complications, hypertension being most prevalent cardiovascular toxic side effect. Currently, it is widely accepted that TKIs-induced involves multiple mechanisms including dysregulation endothelin (ET) axis, reduced bioavailability nitric oxide (NO), imbalance in NO-ROS equilibrium system, rarefaction, activation epithelial sodium calcium channels; nevertheless, excessive ET system appears to be predominantly responsible for this condition. Moreover, studies have demonstrated plays pivotal role driving hypertension. Therefore, review aims explore significance pathogenesis induced by investigate potential therapeutic value antagonists managing caused drugs.

Язык: Английский

---